Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity-Matched Analysis From MRI-Based Study

BACKGROUND AND PURPOSE: Argatroban is widely used for patients with acute branch atheromatous disease (BAD)-related stroke, but its efficacy remains unclear. This study aims to evaluate its clinical outcomes in this patient population. METHODS: A prospective, MRI-based cohort (BAD-study) was conducted across 20 hospitals in China from June 2021 to June 2023, enrolling patients aged 18-80 years with BAD-related stroke within 72 h of onset. Patients were divided into two groups: Argatroban and non-argatroban. The primary outcome was an excellent outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days. Secondary outcomes included good outcome (mRS 0-2), mRS score, Barthel Index score at 90 days, and NIHSS score at 7 days. Logistic regression analyses were performed to assess the association between argatroban and outcomes after propensity score matching (PSM). RESULTS: A total of 467 patients were included, with a median age of 60 years and a median NIHSS score of 4 at admission. Eighty-six patients (18.4%) were in the argatroban group, and 381 patients (81.6%) were in the non-argatroban group. After PSM, excellent outcomes occurred in 60.0% of the argatroban group and 64.2% of the non-argatroban group (odds ratio [OR] = 0.84, 95% CI: 0.47-1.49, p = 0.542). Argatroban was not significantly associated with secondary outcomes and remained ineffective in sensitivity analyses. CONCLUSION: Argatroban was not associated with excellent outcome at 90 days in patients with acute BAD-related stroke. Our study suggests that the risks and benefits of argatroban need reevaluation in patients with BAD-related stroke.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed pharmacology and drug-development research relevant to anticoagulants and leech-derived compounds. Indexed in PubMed and verified against the NCBI record.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Explore how this research connects to clinical practice

More peer-reviewed studies in Drug Development.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)
• In-vitro antileishmanial potential of peptide drug hirudin — Khan H et al. (2017)
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines — Garcia DA, Baglin TP, Weitz JI, Samama MM (2012)
• Direct thrombin inhibitors — Lee CJ, Ansell JE (2011)
• Updates on Use and Monitoring of Direct Thrombin Inhibitors — Navaei A et al. (2026)

Browse all ASH-analysed research →